Publikationen

@article{Schwebke.2017,

title = {Pr\"{u}fung und Deklaration der Wirksamkeit von Desinfektionsmitteln gegen Viren zur Anwendung im human-medizinischen Bereich : Stellungnahme des Arbeitskreises Viruzidie beim Robert Koch-Institut},

author = {I Schwebke and M Eggers and J Gebel and B Geisel and D Glebe and I Rapp and J Steinmann and H F Rabenau},

doi = {10.1007/s00103-016-2509-2},

issn = {1436-9990},

year  = {2017},

date = {2017-01-01},

journal = {Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz},

volume = {60},

number = {3},

pages = {353--363},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Schwebke.2017b,

title = {H\"{a}ndedesinfektionsmittel: Welche Bedeutung und Konsequenzen hat der neue Wirkbereich „begrenzt viruzid PLUS“?},

author = {I Schwebke and M Eggers and J Gebel and B Geisel and J Steinmann and N-O H\"{u}bner and I Rapp and H F Rabenau},

doi = {10.17886/EpiBull-2017-026},

year  = {2017},

date = {2017-01-01},

journal = {Epidemiologisches Bulletin},

number = {18/19},

pages = {171--172},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Pfaefflin.2017,

title = {Short Centrifugation to Ameliorate Turn-Around-Time in Routine Coagulation Testing},

author = {A Pfaefflin and K Schuster and R Braun},

doi = {10.7754/Clin.Lab.2017.170702},

issn = {1433-6510},

year  = {2017},

date = {2017-01-01},

journal = {Clinical laboratory},

volume = {63},

number = {11},

pages = {1945--1947},

abstract = {BACKGROUND 

 

Fast and timely analysis of coagulation parameters is mandatory in hospital laboratories as the results are decisive for diagnosis and treatment in emergency patients. An important factor in TAT (turn-around time) prolongation is centrifugation of all samples prior to analysis. According to literature and most current SOPs (standard operation protocols) centrifugation time is given with 10 minutes at approximately 2,000 g and cannot be reduced without infringement of standards. Thus, we have attempted to minimize TAT by comparing coagulation test results achieved with 5 minutes centrifugation time vs. 10 minutes. If feasible, a shorter centrifugation time will result in further optimized TAT and therefore save critical time to treatment in emergency patients. 

 

METHODS 

 

96 routine clinical samples were tested for prothrombin time (textquotedblQuicktextquotedbl), activated partial prothrombin time (aPTT), thrombin time, fibrinogen, antithrombin III, and D-Dimer with 5 and 10 minutes centrifugation. 405 double measurements were performed. 

 

RESULTS 

 

Correlation of results were for all 6 parameters  0.99. Deviation of the mean was lower than 3% for each parameter. 98.5% of results deviated less than 10%. Although the analysis results for prothrombin time and for antithrombin III show a formal significant difference via Student's t-test, clinically, a difference is not evident. 

 

CONCLUSIONS 

 

Shortening of centrifugation time for coagulation testing seems to have no detrimental effects on the analysis results, and might be sought for routine coagulation testing to achieve shorter turn-around time.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Gro.2017,

title = {Toxoplasmose in der Schwangerschaft und beim Neugeborenen},

author = {U Gro\ss and M Enders and J G Garweg and I Reiter-Owona and L Schrod},

year  = {2017},

date = {2017-01-01},

journal = {p\"{a}diatrische praxis},

volume = {87},

number = {2},

pages = {187--198},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Enders.2017,

title = {Amniocentesis for prenatal diagnosis of cytomegalovirus infection: challenging the 21 weeks' threshold},

author = {M Enders and A Daiminger and S Exler and G Enders},

doi = {10.1002/pd.5107},

issn = {0197-3851},

year  = {2017},

date = {2017-01-01},

journal = {Prenatal diagnosis},

volume = {37},

number = {9},

pages = {940--942},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Enders.2017b,

title = {Prenatal diagnosis of congenital cytomegalovirus infection in 115 cases: a 5 years' single center experience},

author = {M Enders and A Daiminger and S Exler and K Ertan and G Enders and R Bald},

doi = {10.1002/pd.5025},

year  = {2017},

date = {2017-01-01},

urldate = {2017-01-01},

journal = {Prenatal diagnosis},

volume = {37},

pages = {1--10},

abstract = {OBJECTIVE: The objective of this study is to investigate the diagnostic value of invasive prenatal diagnosis (PD) of congenital cytomegalovirus (CMV) infection from amniotic fluid (AF) and fetal blood (FB). METHODS: A retrospective study was conducted on 115 pregnancies with CMV primary infection. A total of 111 AF and 106 FB samples were investigated for various virological and non-virological markers. Detailed ultrasound examinations were performed at time of PD. RESULTS: Overall sensitivity of CMV PCR in FB (75.6%; 95%CI 60-87) and AF (72.7%; 95%CI 57-85) was comparable. In women with amniocentesis textgreater8 weeks between seroconversion and PD, we did not observe significant differences between amniocentesis performed textgreater/=17 + 0 (sensitivity 90.9%; 95%CI 71-99) and textgreater/=20 + 0 gestational weeks (sensitivity 90.0%; 95%CI 68-99). Virological markers in FB were higher in symptomatic compared with asymptomatic fetuses (p textless 0.05). No significant differences were observed for non-virological markers. However, platelet counts textless120 x 10e9/L and beta-2 microglobulin values textgreater14 mg/L were more frequently found in fetuses with severe ultrasound abnormalities compared with fetuses with no or mild abnormalities (p textless 0.001). CONCLUSION: Optimal timing of amniocentesis in women with primary infection in early gestation should be reevaluated in a prospective study. Analysis of FB markers may be beneficial in the individual management of pregnant women with confirmed congenital CMV infection. (c) 2017 John Wiley \& Sons, Ltd},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Ignatius.2016,

title = {Highly specific detection of Cryptosporidium spp. oocysts in human stool samples by undemanding and inexpensive phase contrast microscopy},

author = {R Ignatius and T Klemm and S Zander and J B Gahutu and P Kimmig and F P Mockenhaupt and T Regnath},

doi = {10.1007/s00436-015-4859-3},

year  = {2016},

date = {2016-01-01},

journal = {Parasitology research},

volume = {115},

number = {3},

pages = {1229--1234},

abstract = {To compare phase contrast microscopy (PCM) of unstained slides for the detection of Cryptosporidium spp. oocysts with a commercially available enzyme immunoassay (EIA) for the detection of cryptosporidial antigen in human stool samples, we prospectively analysed by both methods 463 fresh human stool samples obtained from diarrhoeic patients between July and October 2014. Compared with the EIA, the sensitivity, specificity, positive and negative predictive value of PCM were 88.9 % (95 % confidence interval (CI), 66.0-98.1 %), 100 % (95 % CI, 99.0-100 %), 100 % (95 % CI, 77.3-100 %) and 99.6 % (95 % CI, 98.3-100 %), respectively. Additionally, we retrospectively examined with PCM 65 fixed stool samples that had been collected in 2010 from mostly asymptomatic Rwandan children textless5 years of age; 14 of these samples had previously yielded positive results with a highly sensitive real-time (RT)-PCR. PCM detected cryptosporidia in 5/14 RT-PCR-positive samples, and notably, also in one of 51 RT-PCR-negative samples, which was subsequently confirmed by acid-fast staining. Positive and negative percent agreement of PCM with RT-PCR were 35.7 % (95 % CI, 16.2-61.4 %) and 98.0 % (95 % CI, 88.7-100 %), respectively. Positive PCM results were associated with higher RT-PCR cycle threshold values (p = 0.044). In conclusion, PCM offers a highly specific, undemanding and inexpensive method for the laboratory diagnosis of acute human cryptosporidiosis independent of the causative Cryptosporidium species.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Eggers.2016b,

title = {Neuer Wirksamkeitsbereich begrenzt viruzid PLUS -- was ist das?},

author = {M Eggers},

url = {http://www.zbmed.de/ccmedimages/2016/ZBMED-2017135155-3.pdf},

issn = {0172-3790},

year  = {2016},

date = {2016-01-01},

journal = {Hygiene + Medizin},

volume = {41},

number = {12},

pages = {319},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Geipel.2016,

title = {Stellungnahme zum Thema Zika-Virusinfektion},

author = {A Geipel and M Enders and I Mylonas},

doi = {10.1016/S0140­6736(16)30253­7.},

issn = {0016-0237},

year  = {2016},

date = {2016-01-01},

journal = {Frauenarzt},

volume = {57},

number = {6},

pages = {614--617},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Bottcher.2016,

title = {Recombinant Enterovirus A71 Subgenogroup C1 Strains, Germany, 2015},

author = {S B\"{o}ttcher and P E Obermeier and K Neubauer and S Diedrich},

doi = {10.3201/eid2210.160357},

issn = {1080-6040},

year  = {2016},

date = {2016-01-01},

urldate = {2016-01-01},

journal = {Emerging Infectious Diseases},

volume = {22},

number = {10},

pages = {1843--1846},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Rabenau.2016,

title = {2. Mitteilung des DVV/GfV-Fachausschusses Virusdesinfektion zur DVV/RKI-Leitlinie in der Fassung vom 01.12.2014 : Erl\"{a}uterung zur Bedeutung, Anwendung und Berechnung des textquotedblLarge-Volume-Platingstextquotedbl (LVP)},

author = {H F Rabenau and I Schwebke and J Bl\"{u}mel and M Eggers and I Rapp and J Steinmann and H Willkommen},

doi = {10.1007/s00103-016-2325-8},

issn = {1436-9990},

year  = {2016},

date = {2016-01-01},

journal = {Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz},

volume = {59},

number = {4},

pages = {540--542},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Regnath.2016,

title = {Antimicrobial resistance of Neisseria gonorrhoeae isolates in south-west Germany, 2004 to 2015: increasing minimal inhibitory concentrations of tetracycline but no resistance to third-generation cephalosporins},

author = {T Regnath and T Mertes and R Ignatius},

url = {https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2016.21.36.30335},

doi = {10.2807/1560-7917.ES.2016.21.36.30335},

year  = {2016},

date = {2016-01-01},

journal = {Eurosurveillance},

volume = {21},

number = {36},

pages = {30335},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Enders.2016b,

title = {Kinderkrankheiten und Schwangerschaft -- Mumps, Masern und R\"{o}teln},

author = {M Enders and M Biber and S Exler},

doi = {10.1007/s00129-016-3912-3},

issn = {0017-5994},

year  = {2016},

date = {2016-01-01},

journal = {Der Gyn\"{a}kologe},

volume = {49},

number = {8},

pages = {575--581},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Luthgens.2016,

title = {Comment on "The importance of determining the limit of detection of non-invasive prenatal testing methods"},

author = {K L\"{u}thgens and A Binder and D Biskup},

doi = {10.1002/pd.4854},

issn = {0197-3851},

year  = {2016},

date = {2016-01-01},

journal = {Prenatal diagnosis},

volume = {36},

number = {9},

pages = {896--897},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Schalasta.2016b,

title = {Performance of the New Aptima HCV Quant Dx Assay in Comparison to the Cobas TaqMan HCV2 Test for Use with the High Pure System in Detection and Quantification of Hepatitis C Virus RNA in Plasma or Serum},

author = {G Schalasta and A Speicher and A B\"{o}rner and M Enders},

doi = {10.1128/JCM.03236-15},

issn = {0095-1137},

year  = {2016},

date = {2016-01-01},

journal = {Journal of clinical microbiology},

volume = {54},

number = {4},

pages = {1101--1107},

abstract = {Quantitating the level of hepatitis C virus (HCV) RNA is the standard of care for monitoring HCV-infected patients during treatment. The performances of commercially available assays differ for precision, limit of detection, and limit of quantitation (LOQ). Here, we compare the performance of the Hologic Aptima HCV Quant Dx assay (Aptima) to that of the Roche Cobas TaqMan HCV test, version 2.0, using the High Pure system (HPS/CTM), considered a reference assay since it has been used in trials defining clinical decision points in patient care. The assays' performance characteristics were assessed using HCV RNA reference panels and plasma/serum from chronically HCV-infected patients. The agreement between the assays for the 3 reference panels was good, with a difference in quantitation values of textless0.5 log. High concordance was demonstrated between the assays for 245 clinical samples (kappa = 0.80; 95% confidence interval [CI], 0.720 to 0.881); however, Aptima detected and/or quantitated 20 samples that HPS/CTM did not detect, while Aptima did not detect 1 sample that was quantitated by HPS/CTM. For the 165 samples quantitated by both assays, the values were highly correlated (R= 0.98;Ptextless 0.0001). The linearity of quantitation from concentrations of 1.4 to 6 log was excellent for both assays for all HCV genotypes (GT) tested (GT 1a, 1b, 2b, and 3a) (R(2)textgreater 0.99). The assays had similar levels of total and intra-assay variability across all genotypes at concentrations from 1,000 to 25 IU/ml. Aptima had a greater analytical sensitivity, quantitating more than 50% of replicates at 25-IU/ml target. Aptima showed performance characteristics comparable to those of HPS/CTM and increased sensitivity, making it suitable for use as a clinical diagnostic tool on the fully automated Panther platform.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Schalasta.2016c,

title = {Comparative evaluation of the Aptima HIV-1 Quant Dx assay and COBAS TaqMan HIV-1 v2.0 assay using the Roche High Pure System for the quantification of HIV-1 RNA in plasma},

author = {G Schalasta and A B\"{o}rner and A Speicher and M Enders},

doi = {10.1515/cclm-2015-0522},

issn = {1434-6621},

year  = {2016},

date = {2016-01-01},

journal = {Clinical chemistry and laboratory medicine},

volume = {54},

number = {3},

pages = {493--499},

abstract = {BACKGROUND: Quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma has become the standard of care in the management of HIV-infected patients. There are several commercially available assays that have been implemented for the detection of HIV-1 RNA in plasma. Here, the new Hologic Aptima(R) HIV-1 Quant Dx assay (Aptima HIV) was compared to the Roche COBAS(R) TaqMan(R) HIV-1 Test v2.0 for use with the High Pure System (HPS/CTM). METHODS: The performance characteristics of the assays were assessed using commercially available HIV reference panels, dilution of the WHO 3rd International HIV-1 RNA International Standard (WHO-IS) and plasma from clinical specimens. Assay performance was determined by linear regression, Deming correlation analysis and Bland-Altman analysis. RESULTS: Testing of HIV-1 reference panels revealed excellent agreement. The 61 clinical specimens quantified in both assays were linearly associated and strongly correlated. CONCLUSIONS: The Aptima HIV assay offers performance comparable to that of the HPS/CTM assay and, as it is run on a fully automated platform, a significantly improved workflow},

keywords = {},

pubstate = {published},

tppubtype = {article}

}